You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in France

May 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in France with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in France, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in France for free:

The Consumer Health in France market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in France?
  • What are the major brands in France?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Consumer health sees modest, but faster, growth in comparison with 2009

Value sales of consumer health increased slightly in France in 2010. In comparison with 2009, the market registered a faster growth rate. With the more favourable economic context, demand was in general higher. The launch of OTC proton pump inhibitors, previously only available through prescription, was another key driver of growth. Several categories boosted the overall performance, as was the case for antihistamines/allergy remedies (systemic) and probiotic supplements, whose sales saw double-digit growth.

2010 is a year full of important events

Several major events impacted consumer health in 2010. These included the successful launch of OTC proton pump inhibitors; changes in French demographic structure driving the performance of the cranberry, calming and sleeping, and emergency contraception categories; the rise in the price of tobacco and its positive impact on the sales of NRT lozenges and legislation expected to be put into force in 2011, but whose effects were already felt in dietary supplements, weight loss supplements and sports nutrition.

New OTC proton pump inhibitors behind best value share performances

Consumer health remains fragmented, with more than 130 players in operation. Among them Laboratoires McNeil ranked first. With a large portfolio of brands, this player is present in several categories, ranking first in digestive remedies, NRT smoking cessation aids, eye care and adult mouth care. Laboratoires UPSA and Théraplix SA held respectively the second and third positions. However the most important value share rises were registered by other operators, such as Bayer Sante Familiale SAS and Nycomed France SAS, largely due to the launch of their proton pump inhibitors brands.

Chemists/pharmacies continues to be the main distribution channel

Health and beauty retailers accounted for 84% of value sales in 2010. Among them, chemists/pharmacists held the most important share. In 2010, this position grew stronger, as channels such as grocery retailers and non-store retailing saw their value share decline. Consumers continue to prefer to receive the advice of a health professional when it concerns self-medication, which in part explains the slow development of self-service in pharmacies. The fact that some products, including OTC medicines, are exclusively available in chemists/pharmacies also explains their important share.

Low overall performances for the forecast period

Sales of consumer health are expected to be stable in constant value terms over the forecast period. The market is mature and dynamic growth can only be expected from some categories, such as proton pump inhibitors, cranberry and antihistamines/allergy remedies (systemic). The continued propensity of the French to visit doctors in order to have access to semi-ethical drugs (those available both OTC and through prescription) that can be reimbursed, the tightened legislation expected for dietary supplements and increasing competition at a retailing level will be the most important factors inhibiting stronger performances until 2015. OTC emergency contraception is expected to be the best performing category, largely due to higher use of these products in cases of unprotected sex or failure of the usual contraception method. There are also some good prospects for herbal/traditional products, such as the new generation of products within the antiparasitics/lice (head and body) treatments category. They are expected to continue to attract consumers as they are chemical-free and consequently perceived as more natural and safer for health.

Table of Contents

Table of Contents

Consumer Health in France - Industry Overview

EXECUTIVE SUMMARY

Consumer health sees modest, but faster, growth in comparison with 2009

2010 is a year full of important events

New OTC proton pump inhibitors behind best value share performances

Chemists/pharmacies continues to be the main distribution channel

Low overall performances for the forecast period

KEY TRENDS AND DEVELOPMENTS

Switches driving sales growth

Ageing population a key driver for consumer health

Further increases in tobacco prices responsible for new growth of NRT smoking cessation aids

Tightened legislation concerning dietary supplements expected for 2011

Further competition expected at retailing level

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 2 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2005-2010
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 5 Sales of Consumer Health by Region: Value 2005-2010
  • Table 6 Sales of Consumer Health by Region: % Value Growth 2005-2010
  • Table 7 Consumer Health Company Shares by Value 2006-2010
  • Table 8 Consumer Health Brand Shares by Value 2007-2010
  • Table 9 Penetration of Private Label by Category 2005-2010
  • Table 10 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 11 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 12 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 13 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

Advertising

Packaging and Labelling

Distribution

Vitamins and Dietary Supplements Registration and Classification

EU Legislation

Self-medication/Self-care and Preventive Medicine

Generics

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in France - Company Profiles

Arkopharma SA, Laboratoires Pharmaceutiques in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

COMPETITIVE POSITIONING

  • Summary 5 Laboratoires Pharmaceutiques Arkopharma SA: Competitive Position 2010

Bayer Sante Familiale SAS in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Bayer Santé Familiale: Competitive Position 2010

Beaufour-Ipsen SA in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 11 Beaufour-Ipsen SA: Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 12 Beaufour-Ipsen SA: Competitive Position 2010

Cooperation Pharmaceutique Francaise SAS (Cooper) in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 15 Cooperation Pharmaceutique Francaise SAS (Cooper): Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 16 Cooperation Pharmaceutique Francaise SAS (Cooper): Competitive Position 2010

Juva Santé, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 19 Laboratoires Juva Santé: Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 20 Laboratoires Juva Santé: Competitive Position 2010

Laboratoires McNeil in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 23 Laboratoires McNeil: Competitive Position 2010

Laboratoires UPSA SAS in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 26 Laboratoires UPSA: Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 27 Laboratoires UPSA: Competitive Position 2010

Pierre Fabre SA, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 30 Laboratoires Pierre Fabre SA: Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 31 Laboratoires Pierre Fabre SA: Competitive Position 2010

Théraplix SA in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

COMPETITIVE POSITIONING

  • Summary 33 Théraplix SA: Competitive Position 2010

Urgo, Laboratoires in Consumer Health (France)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 36 Laboratoires Urgo: Competitive Position 2010

Adult Mouth Care in France - Category Analysis

HEADLINES

TRENDS

  • Value sales of adult mouth care decreased by 1% in 2010, which was slower than the decline observed in 2009. The category continued to suffer from the strong competition of mouthwashes/dental rinses and Rx products.

SWITCHES

COMPETITIVE LANDSCAPE

  • Adult mouth care is dominated by two leading players that together accounted for a value share of 92% in 2010. Laboratoires McNeil ranked first with a value share of 48%, closely followed by Laboratoires Pierre Fabre SA with a value share of 44%. Both players owned two well-established and well-known brands – Hextril and Alodont (Laboratoires McNeil) and Eludril and Pansoral (Laboratoires Pierre Fabre SA).

PROSPECTS

  • Sales of adult mouth care are expected to post a negative CAGR of 2% in constant value terms over the forecast period. Lack of innovation and investment in advertising will contribute to this anticipated decline. In addition, the category will continue to suffer from the competition presented by Rx products and mouthwashes/dental rinses, which will also push down demand.

CATEGORY DATA

  • Table 14 Sales of Adult Mouth Care: Value 2005-2010
  • Table 15 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 16 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 17 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 18 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 19 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in France - Category Analysis

HEADLINES

TRENDS

  • Consumers continued to be very confident in terms of self-medication with analgesics to relieve pain. However, there remained a lack of investment within the aspirin category, which partly explains the modest performance of analgesics in 2010. Aspirin continued to be threatened by consumers’ preference for acetaminophen and ibuprofen.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires UPSA and Théraplix SA led analgesics in 2010 with value shares of 28% and 27% respectively. Together they controlled more than half of the total category of analgesics in value terms, thanks largely to the performances of Efferalgan brand for the first-ranked player and Doliprane for the second. Both brands were present in acetaminophen, the most valuable category.

PROSPECTS

  • Consumers are expected to remain confident in terms of self-medication with analgesics for pain relief over the forecast period, in particular with acetaminophen and ibuprofen. The category’s performance overall is forecast to suffer from stronger competition from generics and homeopathic products. However, the development of self-service is expected to balance this negative impact, allowing the category to be stable over the forecast period.

CATEGORY DATA

  • Table 20 Sales of Analgesics by Category: Value 2005-2010
  • Table 21 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 22 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 23 Analgesics Company Shares by Value 2006-2010
  • Table 24 Analgesics Brand Shares by Value 2007-2010
  • Table 25 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 26 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in France - Category Analysis

HEADLINES

TRENDS

  • In 2010, value sales of calming and sleeping increased by 4%, a slightly higher growth rate than that observed in 2009. Sales of calming and sleeping continued to benefit from modern lifestyles. Generally busier and more stressed, French people tend to self-medicate with calming and sleeping products in an effort to reduce daily pressures and help them to sleep, particularly with herbal/traditional variants, which are perceived as more natural and less harmful to health. The category also benefited from the ageing population, as in general senior people tend to be more affected by sleeping disorders and anxiety.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires UPSA ranked first within the calming and sleeping category with a value share of 27%, thanks to the performance of its well-known brand Donormyl. Particularly active in terms of communication to both consumers and chemists/pharmacists, Donormyl OTC sales benefit from the fact that this is one of the most commonly-advised brands by doctors and chemists/pharmacists to patients wanting to buy a calming and sleeping product. Bayer Santé Familiale SAS and Jolly-Jattel SARL followed with value shares of 25% and 12% respectively, achieved through their brands Euphytose and Spasmine Jolly.

PROSPECTS

  • The calming and sleeping category is expected to see constant value sales increase at a CAGR of 1% over the forecast period, representing a slowdown in growth compared with the review period. Busy and stressful lifestyles will continue to incite French consumers to self-medicate with OTC products and to reduce the consumption of Rx medicines that have more risks of addiction.

CATEGORY DATA

  • Table 27 Sales of Calming and Sleeping: Value 2005-2010
  • Table 28 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 29 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 30 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 31 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 32 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in France - Category Analysis

HEADLINES

TRENDS

  • Cough, cold and allergy (hay fever) remedies is a category whose performance continues to be highly dependent on several external factors, such as changes in weather conditions or levels of pollution, pollen or flu. In general, consumers are used to self-medicating with products from this category and they did not change their habits in 2010. However, the category faced stronger competition from some homoeopathic remedies. Oscillococcinum, owned by Laboratoires Boiron, for example, continued to see its popularity grow, which inhibited performances of OTC products targeted towards the treatment of flu.

SWITCHES

COMPETITIVE LANDSCAPE

  • Cough, cold and allergy (hay fever) remedies is a fragmented category in France with more than 20 players operating. Among the leading players, Laboratoires Urgo and Ricola AG both hold value shares of 12%. Ricola AG is the leading player of medicated confectionery, one of the most valuable categories, while Laboratoires Urgo is the owner of the Humex brand, which includes a large range of products and was consequently present in several categories.

PROSPECTS

  • No major development is expected for cough, cold and allergy (hay fever) remedies over the forecast period. Consumers are used to self-medicating with these products and no changes are expected in terms of confidence in the future. While some categories, such as antihistamines/allergy remedies (systemic), are expected to perform well as a result of a growing demand among the rising number of allergy sufferers, more traditional medicines to treat flu will face difficulties due to the growing popularity of homoeopathic products. Meanwhile, operators of leading brands are likely to continue to enlarge their range of products in order to better respond to different consumers’ needs, but also to gain more visibility on shelves, in particular when their products are located on the self-service shelves of chemists/pharmacies. To compete for sales, they are also expected to continue to invest in advertising directly to consumers and to improve their packaging.

CATEGORY DATA

  • Table 33 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 34 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 35 Sales of Decongestants by Category: Value 2005-2010
  • Table 36 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 37 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 38 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 39 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 40 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 41 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 42 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in France - Category Analysis

HEADLINES

TRENDS

  • The key story of digestive remedies in 2010 was the emergence of the OTC proton pump inhibitors category with the launch of a first brand in November 2009 and two more during 2010. This new category of products came to extend the digestive remedies category as a whole, being largely responsible for the growth of 10% observed in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • More than 20 players were operating within the digestive remedies category in 2010. Among them, Laboratoires McNeil led with a value share of 12%. This player was followed by three operators (Théraplix SA, Laboratoires Céphalon and Bayer Sante Familiale SAS), all of which had value shares between 9% and 10%. In general, they had a large range of brands positioned in different categories, some of them well established and with a high value share in the main category in which they operate.

PROSPECTS

  • The digestive remedies category is expected to continue to benefit from the performance of OTC proton pump inhibitors over the forecast period. These new products will support overall sales of this category until 2015.

CATEGORY DATA

  • Table 43 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 44 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 45 Digestive Remedies Company Shares by Value 2006-2010
  • Table 46 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 47 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 48 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in France - Category Analysis

HEADLINES

TRENDS

  • In 2010, products to clean the ear continued to enjoy high receptivity in France, largely because French consumers continued to lower their usage of cotton buds, while players within the category worked to sustain their brands with mass media advertising.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires Chauvin SA led the ear care category in 2010 with a value share of 60%. This player operates several brands within the category, including Cerulyse, the leading OTC ear care brand.

PROSPECTS

  • Over the forecast period, sales of ear care are expected to post a negative CAGR of 2% in constant value terms. Players within this category are not expected to change their existing strategies and with only a few investments in terms of new products and advertising, it will be very difficult for the ear care category to register a stronger performance.

CATEGORY DATA

  • Table 49 Sales of Ear Care: Value 2005-2010
  • Table 50 Sales of Ear Care: % Value Growth 2005-2010
  • Table 51 Ear Care Company Shares by Value 2006-2010
  • Table 52 Ear Care Brand Shares by Value 2007-2010
  • Table 53 Forecast Sales of Ear Care: Value 2010-2015
  • Table 54 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in France - Category Analysis

HEADLINES

TRENDS

  • Value sales of emergency contraception again registered growth in France, rising by 9% in current value terms. This increase was essentially driven by higher demand, as unit prices were stable. To prevent unplanned pregnancies, in particular after unprotected sex or contraception failure, French women continued to buy the “morning after pill”. However, in comparison with the previous year, value sales in 2010 increased at a marginally slower growth rate, explained in part by a higher use of condoms. Public institutions continued to undertake communication campaigns to encourage the use of condoms in order to prevent sexually transmitted diseases such as AIDS, a factor that undeniably impacts demand for emergency contraception.

COMPETITIVE LANDSCAPE

  • Laboratoires HRA Pharma SA, the European operator of the NorLevo brand, continued to lead emergency contraception in France with a value share of 73% in 2010. The domestic player, Laboratoires Biogaran, accounted for the remaining share, thanks to the performance of its Lévonorgestrel Biogaran brand.

PROSPECTS

  • Sales of emergency contraception are expected to increase at a CAGR of 6% in constant value terms over the forecast period. French women are forecast to continue to opt for this type of product when the need arises. In comparison with the review period, the category will see slower growth. The use of condoms, recommended by public institutions as the best way to prevent sexually transmitted diseases, for example, will continue to inhibit the stronger growth of emergency contraception in the medium and long term.

CATEGORY DATA

  • Table 55 Sales of Emergency Contraception: Value 2005-2010
  • Table 56 Sales of Emergency Contraception: % Value Growth 2005-2010
  • Table 57 Emergency Contraception Company Shares by Value 2006-2010
  • Table 58 Emergency Contraception Brand Shares by Value 2007-2010
  • Table 59 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 60 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in France - Category Analysis

HEADLINES

TRENDS

  • A new OTC brand within allergy eye care created some dynamism and increased competition in the category, which helped the overall eye care category to avoid a decline in sales in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • Laboratoires McNeil ranked first with a value share of 28% in 2010, mainly thanks to the performance of its Dacryosérum brand, the leader within standard eye care. Cooperation Pharmaceutique Francaise SAS (Cooper) and Ciba Vision SAS were ranked second and third in 2010 with value shares of 17% and 9% respectively. Both operators offer several OTC eye care brands.

PROSPECTS

  • Eye care is expected to decline at a CAGR of 1% in constant value terms over the forecast period. Both allergy eye care and standard eye care are forecast to post a negative performance. No important variation in terms of volume growth is expected and the main players are expected to maintain their existing strategies, which are characterised by a lack of investment in advertising and new product development. This is because eye care is not a strategic category for them and future performances will be based on the recognition their brands already enjoy among consumers.

CATEGORY DATA

  • Table 61 Sales of Eye Care by Category: Value 2005-2010
  • Table 62 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 63 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 64 Eye Care Company Shares by Value 2006-2010
  • Table 65 Eye Care Brand Shares by Value 2007-2010
  • Table 66 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 67 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in France - Category Analysis

HEADLINES

TRENDS

  • The popularity of herbal/traditional products continued to increase in France in 2010. Demand continued to grow largely because these products are considered more “natural” and consequently less harmful to health. This is the case despite this product type being generally more expensive than standard OTC medicines.

COMPETITIVE LANDSCAPE

  • Ricola AG led herbal/traditional products in 2010 with a value share of 16%. This player is present in herbal/traditional cough, cold and allergy (hay fever) remedies, one of the most important herbal/traditional categories, with its brand Ricola, which leads the medicated confectionery category.

PROSPECTS

  • Herbal/traditional products will continue to benefit from the fact that French consumers are increasingly open to self-medication with these products, in part because they perceive them to be more natural and, consequently, less harmful to health.

CATEGORY DATA

  • Table 68 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 69 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 70 Herbal/Traditional Products Company Shares 2006-2010
  • Table 71 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 72 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 73 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in France - Category Analysis

HEADLINES

TRENDS

  • In 2010, French consumers were seen to be increasingly open to self-medication with medicated skin care products, in particular with products perceived to be more natural, opting to reduce visits to doctors to obtain a specific treatment for such minor ailments, although semi-ethical drugs and Rx medicines continued to be popular because they are reimbursed. This trend, reinforced by the growing availability of OTC products in self-service areas of chemists/pharmacies, attracted new operators, such as the pharmaceutical company Galderma, which launched a broad range products within OTC medicated skin care in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • Around 40 different players were operating within medicated skin care in France in 2010. Laboratoires Pierre Fabre SA remained the leader with a value share of 13%. This player owns several well-established brands present in a number of categories, including Avène, Ducray, Mycoster and Cétavlon, which ensure a good overall performance. Laboratoires Pierre Fabre was closely followed by Laboratoires McNeil, which accounted for 12% of overall value sales.

PROSPECTS

  • Further competition is expected within the medicated skin care category over the forecast period. Reluctant to visit a doctor for minor complaints, but also stimulated by a larger self-service offering, French consumers are expected to self-medicate further when experiencing skin care problems. In order to take advantage of this potential, some players, such as the new entrant Galderma, are forecast to enlarge their OTC portfolios during the forecast period.

CATEGORY DATA

  • Table 74 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 75 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 76 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 77 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 78 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 79 Acne Treatments Brand Shares by Value 2007-2010
  • Table 80 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 81 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 82 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in France - Category Analysis

HEADLINES

TRENDS

  • The current restrictions in terms of smoking in public spaces are undeniably responsible for changes in the consumption habits of smokers and they explain the overall awareness among smokers of the need to diminish their consumption of tobacco, a trend which continued to positively impact NRT smoking cessation aids in 2010, particularly the oral products (NRT lozenges and NRT gum). However this legislation, put into force some years ago, seems to have reached its limits in terms of impact, as there was a slight rise in the number of French smokers in 2010, according to Euromonitor International, despite the successive increases in tobacco prices.

SWITCHES

COMPETITIVE LANDSCAPE

  • Only four players operate within the NRT smoking cessation aids in France. Laboratoires McNeil was the leading company in 2010 with a value share of 51%. This operator of the Nicorette brand offered a large range of products in all the categories with the exception of RT lozenges. Laboratoires Pierre Fabre SA was ranked second with a value share of 26% in 2010. The company is present in NRT gum, NRT lozenges and NRT patches with the brands Nicogum, Nicopass and Nicopatch. The rest of the category was divided between GlaxoSmithKline Santé Grand Public SAS and Novartis Group France SA. The presence of private label products remained minor in 2010.

PROSPECTS

  • The performance of NRT smoking cessation aids is highly dependent on public health policy. If the government decides to work towards the reduction of certain diseases such as cancer and adopts specific measures for this purpose, there is likely to be a direct impact on sales of OTC NRT smoking cessation aids. According to players operating within this category, following the rise of tobacco prices at the end of 2010, a new increase was forecast for the beginning of 2011. In fact, the government is expected to continue to use the price of tobacco as a tool to reduce diseases resulting from its consumption. If this new measure is adopted, this will again drive sales of NRT smoking cessation aids in the short term.

CATEGORY INDICATORS

  • Table 83 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 84 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 85 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 86 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 87 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 88 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 89 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 90 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

Sports Nutrition in France - Category Analysis

HEADLINES

TRENDS

  • The sports nutrition category continued to perform positively in 2010. The number of consumers who opt for sports nutrition to help them to build the body they desire increased, thus stimulating volume sales and consequently value sales.

COMPETITIVE LANDSCAPE

  • EA Pharma SA led sports nutrition in 2010 with a value share of 45%. The Eafit brand has a strong reputation in France and is present in several distribution channels. Ranked second was the private label brand Aptonia owned by Decathlon SA. Aptonia is the best-selling sports nutrition brand within the retailing network owned by this major player. In addition to its offer of a large range of products within sports nutrition, the Aptonia brand benefits from being placed in the best strategic positions on the shelves, a situation that supported the brand’s 15% value share recorded in 2010. Ranked third was Weider Fitness SARL with its Weider brand, which registered a value share of 11%.

PROSPECTS

  • Higher demand from people who use sports nutrition products to help them build up their body will continue to stimulate value sales within the category over the forecast period. In order to appeal to a larger consumer base, manufacturers are expected to invest in products with a lower dosage of protein in an effort to increase segmentation. By so doing it is hoped that women as well as men will be attracted to the category. Meanwhile, products backed by proven scientific research or in line with new legislation requirements will have greater potential to perform better in the short term.

CATEGORY DATA

  • Summary 37 Sports Nutrition, category rankings 2010
  • Table 91 Sales of Sports Nutrition: Value 2005-2010
  • Table 92 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 93 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 94 Sports Nutrition Company Shares 2006-2010
  • Table 95 Sports Nutrition Brand Shares 2007-2010
  • Table 96 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 97 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in France - Category Analysis

HEADLINES

TRENDS

  • The most important factor affecting vitamins and dietary supplements in 2010 was the forthcoming tightening of legislation, expected to be put into force in 2011. In general, players within dietary supplements reduced their investment in new products and started to reformulate products already available on the market. In addition, with the entrance of new players until then confined to the OTC segment, the competitive landscape started to evolve.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • More than 50 players were operating within vitamins and dietary supplements in France in 2010. Among all of them, Laboratoires Pharmaceutiques Arkopharma SA was the only one with a double-digit value share (12%). This operator offers a large range of brands and consequently maintains a presence in several categories within vitamins and dietary supplements. Arkogélules, for example, is a well-established brand with a large portfolio of products.

PROSPECTS

  • The competitive landscape of vitamins and dietary supplements is expected to evolve further over the forecast period. Small players operating in this category are likely to experience more difficulties due to a legislative context that is predicted to favour major players, as requirements to maintain or launch products are set to increase. The number of references is expected to shrink as manufacturers will need to prove the promises made about the products on the packaging. Attracted by this new context, the number of pharmaceutical players coming from the OTC environment and investing in dietary supplements is expected to grow. It is possible that some manufacturers will seek to specialise according to segments over the course of 2011 in order to be able to better respond to the new legislative framework.

CATEGORY DATA

  • Summary 38 Dietary Supplements: Brand Ranking by Positioning 2010
  • Table 98 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 99 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 100 Dietary Supplements by Positioning 2005-2010
  • Table 101 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 102 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 103 Vitamins Brand Shares by Value 2007-2010
  • Table 104 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 105 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 106 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in France - Category Analysis

HEADLINES

TRENDS

  • More confident about the future, French people started to buy traditional products such as slimming teas and meal replacement slimming within weight management to control their weight and to slim in 2010. However, this was a timid recovery, as all the other categories performed negatively. A low level of product innovation can explain in part the lack of dynamism evident in some categories. The direct competition presented by Alli from GlaxoSmithKline SA-NV is another contributing factor behind the weak performances. There is also a combination of several other negative factors, such as the lack of visibility of the product offer, less space on retailers’ shelves and the fallout of unfulfilled promises.

COMPETITIVE LANDSCAPE

  • Weight management is fragmented with more than 20 players operating within it. Nutrition & Santé SAS is ranked first with a value share over 23%. It leads the largest category, meal replacement slimming, thanks to the performance of its brand Gerlinéa, which is available in the main grocery retailers. The company is also present in chemists/pharmacies with its brand Milical. GlaxoSmithKline SA-NV is ranked second with a value share of 12% thanks to Alli, the only OTC obesity brand available in the market. This player was followed by Herbalife International France SA, a major player within direct selling that offers a large range of meal replacement slimming products and weight loss supplements; it accounted for 9% of the total value sales in 2010.

PROSPECTS

  • The context surrounding weight management is positive in France, a situation that is likely to continue over the forecast period. Obesity is a major issue in the country because it can contribute to levels of illness, an important aspect when the government is trying to reduce expenses within the healthcare system. Besides, in general, people do not want to be overweight.

CATEGORY DATA

  • Table 107 Sales of Weight Management: Value 2005-2010
  • Table 108 Sales of Weight Management: % Value Growth 2005-2010
  • Table 109 Weight Management Company Shares 2006-2010
  • Table 110 Weight Management Brand Shares 2007-2010
  • Table 111 Forecast Sales of Weight Management: Value 2010-2015
  • Table 112 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in France - Category Analysis

HEADLINES

TRENDS

  • Wound care operators’ efforts continued to focus on the most valuable category within wound care. They continued to launch new sticking plasters/adhesive bandages using cartoon characters to target children or innovative products offering greater technical advances and patient comfort.

COMPETITIVE LANDSCAPE

  • Laboratoires Urgo led wound care in 2010 with a value share of 33%. The Urgo brand, present in chemists/pharmacies, continued to lead sticking plasters/adhesive bandages. The second- and third-ranked operators were Laboratoires Mercurochrome and Beiersdorf (France) SA. Both players offered a large range of products covering all the categories of wound care, sold through the brands Laboratoires Mercurochrome and Hansaplast respectively; these are both well established in the main grocery retailers.

PROSPECTS

  • Value sales of wound care are expected to see no movement over the forecast period. Demand for wound care remains occasional and remains focused primarily on the purchase of sticking plasters/adhesive bandages, which is expected to see constant value sales rise at a CAGR of 7% over the forecast period.

CATEGORY DATA

  • Table 113 Sales of Wound Care by Category: Value 2005-2010
  • Table 114 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 115 Wound Care Company Shares by Value 2006-2010
  • Table 116 Wound Care Brand Shares by Value 2007-2010
  • Table 117 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 118 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Cranberry
            • Isoflavones
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Lecithin
            • Yeast
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Child-Specific Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Child-Specific Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Child-Specific Consumer Health
      • Child-Specific Analgesics
        • Child-Specific Acetaminophen
        • Child-Specific Aspirin
        • Child-Specific Combination Products - Analgesics
        • Child-Specific Diclofenac
        • Child-Specific Dipyrone
        • Child-Specific Ibuprofen
        • Child-Specific Ketoprofen
        • Child-Specific Naproxen
      • Child-Specific Cough, Cold and Allergy Remedies
        • Child-Specific Allergy Remedies
        • Child-Specific Cough/Cold Remedies
      • Child-Specific Digestive Remedies
        • Child-Specific Diarrhoeal Remedies
        • Child-Specific Indigestion and Heartburn Remedies
        • Child-Specific Laxatives
        • Child-Specific Motion Sickness Remedies
      • Child-Specific Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Child-Specific Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking incidence

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices % growth
  • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices % growth
  • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices % growth
  • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices % growth
  • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

RELATED

Country Report

Consumer Lifestyle

Future Demographic

Country Report